Hub : Traits :

Diabetes diagnosed by doctor

132 significantly associated models · 50 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	39295972	40737589	3	1	1.8e-08	7.2e-07	6.6e-02	86	RP11-69E11.4
2	1	119761038	120687115	2	1	4.2e-08	3.9e-08	1.0e+00	100	NOTCH2
3	1	213759712	215206914	1	1	6.9e-08	3.5e-09	1.6e-03	72	SMYD2
4	2	26655745	28402863	7	1	2.3e-12	7.6e-13	1.0e+00	100	FNDC4
5	2	42767044	44157441	2	1	3.8e-12	4.7e-12	1.0e+00	100	AC010883.5
6	3	22998569	23879862	1	1	9.1e-09	3.7e-10	5.8e-03	81	UBE2E2
7	3	48757291	50800146	4	2	3.3e-09	1.1e-08	9.8e-03	80	RBM6 TCTA
8	3	185112300	185786406	1	1	5.9e-21	8.7e-27	6.4e-08	74	IGF2BP2
9	4	5575751	7002344	1	1	4.9e-17	8.8e-18	2.8e-04	82	WFS1
10	4	103020804	104487361	1	1	1.2e-07	1.8e-05	4.5e-04	33	UBE2D3
11	6	6582123	8009760	1	1	1.3e-10	1.5e-07	9.1e-04	60	SSR1
12	7	27623776	28468319	1	1	1.9e-14	3.6e-15	8.9e-03	89	JAZF1
13	7	73624615	74494207	1	1	1.1e-07	3.3e-07	1.0e+00	100	PMS2P5
14	7	102334106	103489729	1	1	8.9e-08	8.6e-07	4.9e-01	98	NAPEPLD
15	7	156687822	157308348	1	1	6.0e-08	3.8e-08	7.5e-02	90	UBE3C
16	8	40811597	42450441	1	2	3.9e-10	7.1e-11	1.0e+00	100	ANK1
17	8	145504343	146293414	1	1	1.6e-07	1.1e-05	9.5e-06	-1	ZNF517
18	10	11693166	13569805	1	1	8.8e-08	1.2e-08	1.6e-02	82	CAMK1D
19	10	80443273	81901722	1	1	1.4e-08	5.0e-12	3.6e-05	64	ZCCHC24
20	10	93657148	95151622	3	1	8.1e-18	1.7e-18	2.2e-03	88	EIF2S2P3
21	10	113511441	115622375	2	1	4.1e-45	3.7e-150	7.0e-113	25	TCF7L2
22	11	16709350	18106069	3	1	1.2e-09	1.5e-10	1.0e+00	100	KCNJ11
23	12	27677505	28173672	1	1	2.1e-07	1.2e-06	5.6e-01	99	LOC100133893
24	15	89680384	91135411	3	1	2.0e-09	1.8e-08	8.0e-01	100	AP3S2
25	16	52772129	54224557	1	1	4.5e-08	1.4e-22	7.4e-21	8	RBL2
26	16	69736851	70139542	1	1	1.9e-07	1.5e-07	1.0e+00	100	CLEC18A
27	17	40120771	41510850	1	1	5.1e-08	4.8e-08	1.0e+00	100	TUBG2
28	19	45114009	45618902	1	1	2.6e-07	1.7e-07	1.1e-06	13	PVRL2
29	20	31701333	33116483	1	1	1.7e-07	2.5e-07	1.0e+00	100	CHMP4B
30	20	61679007	62912463	1	1	3.1e-08	4.6e-08	1.0e+00	100	ZBTB46

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Type 2 Diabetes (T2D) (2018)	26.89	31	24	53.3	0.99	2.9e-30	AC010883.5 ANK1 AP3S2 CAMK1D CHMP4B CLEC18A EIF2S2P3 FNDC4 IGF2BP2 JAZF1 KCNJ11 LOC100133893 NAPEPLD NOTCH2 PMS2P5 PVRL2 RBL2 RBM6 RP11-69E11.4 SMYD2 SSR1 TCF7L2 TCTA TUBG2 UBE2D3 UBE2E2 UBE3C WFS1 ZBTB46 ZCCHC24 ZNF517
Diabetes (self-reported)	23.98	31	17	37.8	1.00	3.5e-32	AC010883.5 ANK1 AP3S2 CAMK1D CHMP4B CLEC18A EIF2S2P3 FNDC4 IGF2BP2 JAZF1 KCNJ11 LOC100133893 NAPEPLD NOTCH2 PMS2P5 PVRL2 RBL2 RBM6 RP11-69E11.4 SMYD2 SSR1 TCF7L2 TCTA TUBG2 UBE2D3 UBE2E2 UBE3C WFS1 ZBTB46 ZCCHC24 ZNF517
Medication: Metformin	18.83	24	10	22.2	0.99	1.2e-22	AC010883.5 ANK1 AP3S2 CAMK1D EIF2S2P3 FNDC4 IGF2BP2 JAZF1 KCNJ11 PMS2P5 PVRL2 RBL2 RBM6 RP11-69E11.4 SSR1 TCF7L2 TCTA TUBG2 UBE2D3 UBE2E2 UBE3C WFS1 ZBTB46 ZCCHC24
Triglycerides	13.84	3	2	4.4	0.00	1.0e+00	FNDC4 PVRL2 RP11-69E11.4
Diabetes (father)	12.11	11	4	8.9	1.00	1.2e-10	AC010883.5 ANK1 AP3S2 EIF2S2P3 FNDC4 IGF2BP2 JAZF1 LOC100133893 SSR1 TCF7L2 TUBG2
Type 2 Diabetes (T2D) (2012)	11.72	12	5	11.1	0.97	9.2e-08	AC010883.5 ANK1 EIF2S2P3 IGF2BP2 JAZF1 KCNJ11 LOC100133893 SSR1 TCF7L2 UBE2E2 WFS1 ZCCHC24
Diabetes (mother)	10.63	10	4	8.9	0.98	3.8e-07	AC010883.5 ANK1 CAMK1D EIF2S2P3 FNDC4 IGF2BP2 TCF7L2 UBE2E2 UBE3C WFS1
Medication: Gliclazide	9.73	8	2	4.4	0.99	2.4e-06	EIF2S2P3 IGF2BP2 JAZF1 KCNJ11 TCF7L2 UBE2E2 UBE3C WFS1
Illnesses of siblings: Diabetes	7.86	7	3	6.7	0.97	2.5e-04	CAMK1D EIF2S2P3 IGF2BP2 PMS2P5 RBM6 TCF7L2 WFS1
Fasting Glucose	5.65	2	1	2.2	0.00	1.0e+00	FNDC4 SMYD2
Alcohol intake frequency.	5.49	6	5	11.1	0.28	6.0e-01	FNDC4 PMS2P5 RBM6 TCTA TUBG2 UBE2D3
Pulse rate, automated reading	5.33	8	7	15.6	0.23	5.9e-01	FNDC4 JAZF1 LOC100133893 RBL2 RBM6 RP11-69E11.4 TCTA WFS1
Eye problems/disorders: Diabetes related eye disease	4.98	3	0	0.0	0.00	1.0e+00	IGF2BP2 TCF7L2 WFS1
High cholesterol (Self-reported)	4.82	1	1	2.2	0.00	1.0e+00	FNDC4
Medication: Cholesterol lowering	4.73	5	1	2.2	0.22	7.3e-01	CHMP4B FNDC4 IGF2BP2 TCF7L2 TCTA
Cholesterol lowering medication	4.38	3	1	2.2	0.00	1.0e+00	FNDC4 TCF7L2 UBE3C
Medication for cholesterol, blood pressure or diabetes	4.16	7	0	0.0	-0.66	1.1e-01	CAMK1D CHMP4B FNDC4 IGF2BP2 RBM6 TCTA ZBTB46
Gout (self-reported)	4.01	1	1	2.2	0.00	1.0e+00	FNDC4
Number of treatments/medications taken	3.90	4	2	4.4	0.56	4.4e-01	FNDC4 PMS2P5 RBM6 UBE2D3
Medication: Simvastatin	3.88	2	1	2.2	0.00	1.0e+00	FNDC4 TCF7L2
Number of self-reported non-cancer illnesses	3.87	7	2	4.4	0.58	1.7e-01	FNDC4 IGF2BP2 JAZF1 PMS2P5 RBM6 UBE2D3 ZBTB46
Medication: Atorvastatin	3.84	2	1	2.2	0.00	1.0e+00	FNDC4 TCF7L2
Body mass index (BMI)	3.62	12	6	13.3	0.30	3.4e-01	CLEC18A FNDC4 JAZF1 KCNJ11 PMS2P5 PVRL2 RBM6 RP11-69E11.4 TCF7L2 TCTA TUBG2 UBE2D3
Crohns Disease (2017)	3.56	8	3	6.7	-0.73	4.0e-02	AC010883.5 FNDC4 JAZF1 NOTCH2 PMS2P5 RBM6 TCTA TUBG2
Birth weight	3.56	4	2	4.4	0.01	9.9e-01	ANK1 EIF2S2P3 SMYD2 SSR1
Long-standing illness, disability or infirmity	3.54	5	0	0.0	0.96	8.3e-03	IGF2BP2 PMS2P5 RBM6 RP11-69E11.4 ZBTB46
Medication: Allopurinol	3.47	1	1	2.2	0.00	1.0e+00	FNDC4
BMI	3.41	13	9	20.0	0.34	2.6e-01	CLEC18A FNDC4 JAZF1 KCNJ11 NAPEPLD PMS2P5 RBM6 RP11-69E11.4 TCF7L2 TCTA TUBG2 UBE2D3 ZCCHC24
Cardiovascular Disease	3.39	9	4	8.9	0.61	7.9e-02	FNDC4 IGF2BP2 KCNJ11 PMS2P5 TCTA TUBG2 UBE2D3 ZBTB46 ZNF517
Alcohol intake versus 10 years previously	3.34	3	2	4.4	0.00	1.0e+00	FNDC4 RBM6 RP11-69E11.4
Medication for cholesterol	3.28	3	1	2.2	0.00	1.0e+00	FNDC4 RBL2 ZBTB46
Impedance of whole body	3.28	9	5	11.1	-0.14	7.1e-01	AC010883.5 CLEC18A FNDC4 JAZF1 KCNJ11 PMS2P5 RBM6 TCF7L2 UBE2D3
Leg fat mass (left)	3.28	9	4	8.9	0.41	2.8e-01	CLEC18A FNDC4 NAPEPLD PMS2P5 RBM6 TCF7L2 TCTA TUBG2 ZCCHC24
Waist Hip Ratio (WHR)	3.26	10	8	17.8	0.87	9.3e-04	AC010883.5 EIF2S2P3 IGF2BP2 JAZF1 KCNJ11 RBL2 TCF7L2 TCTA TUBG2 ZCCHC24
Taking other prescription medications	3.25	3	1	2.2	0.00	1.0e+00	PMS2P5 RBM6 UBE2D3
Waist circumference	3.21	9	5	11.1	0.51	1.6e-01	CLEC18A FNDC4 PMS2P5 RBM6 RP11-69E11.4 TCF7L2 TCTA TUBG2 ZCCHC24
Leg fat mass (right)	3.21	9	4	8.9	0.41	2.7e-01	CLEC18A FNDC4 NAPEPLD PMS2P5 RBM6 TCF7L2 TCTA TUBG2 ZCCHC24
Impedance of leg (left)	3.17	10	6	13.3	-0.36	3.1e-01	AC010883.5 CLEC18A FNDC4 JAZF1 KCNJ11 PMS2P5 RBL2 RBM6 RP11-69E11.4 TUBG2
Pulse rate	3.14	3	2	4.4	0.00	1.0e+00	FNDC4 RBL2 TCTA
Impedance of arm (left)	3.14	8	5	11.1	-0.15	7.2e-01	AC010883.5 FNDC4 JAZF1 KCNJ11 RBM6 TCF7L2 TCTA UBE2D3
Overall health rating	3.14	5	1	2.2	0.99	1.7e-03	PMS2P5 PVRL2 RBL2 RBM6 UBE2D3
Leg fat percentage (left)	3.14	9	4	8.9	0.39	3.0e-01	CLEC18A PMS2P5 RBL2 RBM6 TCF7L2 TCTA TUBG2 UBE2D3 ZCCHC24
Leg fat percentage (right)	3.02	8	4	8.9	0.31	4.6e-01	CLEC18A PMS2P5 RBL2 RBM6 TCF7L2 TCTA TUBG2 ZCCHC24
Vascular/heart problems diagnosed by doctor	3.01	7	2	4.4	-0.93	2.4e-03	IGF2BP2 KCNJ11 PMS2P5 RBL2 TCTA UBE2D3 ZBTB46
Impedance of leg (right)	3.00	10	7	15.6	-0.34	3.4e-01	AC010883.5 CLEC18A FNDC4 JAZF1 KCNJ11 PMS2P5 RBL2 RBM6 RP11-69E11.4 TUBG2
Impedance of arm (right)	2.96	7	5	11.1	-0.10	8.4e-01	FNDC4 JAZF1 KCNJ11 RBM6 TCF7L2 TCTA UBE2D3
Arm fat mass (right)	2.94	9	4	8.9	0.48	1.9e-01	CLEC18A FNDC4 NAPEPLD PMS2P5 RBM6 RP11-69E11.4 TCF7L2 TCTA TUBG2
Arm fat mass (left)	2.94	8	4	8.9	0.44	2.8e-01	CLEC18A FNDC4 PMS2P5 RBM6 RP11-69E11.4 TCF7L2 TCTA TUBG2
Blood Platelet Count	2.92	9	5	11.1	-0.33	3.9e-01	AC010883.5 AP3S2 EIF2S2P3 FNDC4 IGF2BP2 KCNJ11 RP11-69E11.4 UBE2E2 ZCCHC24
Medication: Ramipril	2.90	1	0	0.0	0.00	1.0e+00	UBE2D3
Hypertension (Self-reported)	2.88	7	2	4.4	0.98	6.1e-05	KCNJ11 PMS2P5 RBL2 TCTA UBE2D3 ZBTB46 ZNF517
High blood pressure	2.86	8	2	4.4	0.99	5.8e-06	CAMK1D KCNJ11 PMS2P5 RBL2 TCTA UBE2D3 ZBTB46 ZNF517
Arm predicted mass (left)	2.85	7	2	4.4	0.77	4.4e-02	FNDC4 JAZF1 NAPEPLD RBL2 RBM6 SSR1 TCTA
Weight	2.82	10	4	8.9	0.45	1.9e-01	CLEC18A FNDC4 NAPEPLD PMS2P5 RBL2 RBM6 RP11-69E11.4 TCF7L2 TCTA TUBG2
Arm fat-free mass (right)	2.82	7	3	6.7	0.77	4.4e-02	FNDC4 JAZF1 NAPEPLD RBL2 RBM6 SSR1 TCTA
Arm fat-free mass (left)	2.82	7	2	4.4	0.77	4.2e-02	FNDC4 JAZF1 NAPEPLD RBL2 RBM6 SSR1 TCTA
Medication: Aspirin	2.80	1	0	0.0	0.00	1.0e+00	IGF2BP2
Medication: Aspirin	2.79	1	0	0.0	0.00	1.0e+00	IGF2BP2
Irritable Bowel Disease (IBD)	2.77	5	2	4.4	-1.00	3.0e-04	AC010883.5 FNDC4 PMS2P5 RBM6 TUBG2
Arm predicted mass (right)	2.77	7	2	4.4	0.76	4.6e-02	FNDC4 JAZF1 NAPEPLD RBL2 RBM6 SSR1 TCTA
Whole body fat mass	2.74	6	4	8.9	0.14	7.9e-01	CLEC18A PMS2P5 RBM6 TCF7L2 TCTA TUBG2
Medication: Blood pressure	2.72	4	0	0.0	1.00	8.7e-04	CAMK1D PMS2P5 UBE2D3 ZBTB46
Medication: Blood pressure	2.72	3	1	2.2	0.00	1.0e+00	KCNJ11 TCTA ZBTB46
Crohns Disease (2012)	2.68	4	0	0.0	-0.99	1.4e-02	AC010883.5 FNDC4 RBM6 TCTA
Wheeze or whistling in the chest in last year	2.68	1	1	2.2	0.00	1.0e+00	RBM6
Arm fat percentage (left)	2.68	7	3	6.7	0.31	5.0e-01	CLEC18A PMS2P5 RBM6 RP11-69E11.4 TCF7L2 TCTA TUBG2
Arm fat percentage (right)	2.67	7	3	6.7	0.31	4.9e-01	CLEC18A PMS2P5 RBM6 RP11-69E11.4 TCF7L2 TCTA TUBG2
Basal metabolic rate	2.67	9	3	6.7	0.75	2.1e-02	FNDC4 JAZF1 NAPEPLD RBL2 RBM6 RP11-69E11.4 SSR1 TCTA TUBG2
Illnesses of father: None of the above (group 1)	2.66	1	0	0.0	0.00	1.0e+00	CAMK1D
Whole body water mass	2.64	8	3	6.7	0.70	5.1e-02	FNDC4 JAZF1 NAPEPLD RBL2 RBM6 RP11-69E11.4 SSR1 TCTA
Alzheimer’s Disease (including proxy)	2.63	1	1	2.2	0.00	1.0e+00	PVRL2
Breast Cancer	2.62	3	1	2.2	0.00	1.0e+00	NOTCH2 PMS2P5 TCF7L2
Whole body fat-free mass	2.60	8	3	6.7	0.70	5.1e-02	FNDC4 JAZF1 NAPEPLD RBL2 RBM6 RP11-69E11.4 SSR1 TCTA
Age at First Birth	2.59	2	2	4.4	0.00	1.0e+00	RBM6 TCTA
Trunk fat-free mass	2.56	7	4	8.9	0.70	8.1e-02	FNDC4 JAZF1 NAPEPLD RBL2 RBM6 RP11-69E11.4 SSR1
Trunk predicted mass	2.56	7	4	8.9	0.70	8.2e-02	FNDC4 JAZF1 NAPEPLD RBL2 RBM6 RP11-69E11.4 SSR1
Age at last live birth	2.55	2	1	2.2	0.00	1.0e+00	EIF2S2P3 RBM6
Illnesses of siblings	2.54	2	0	0.0	0.00	1.0e+00	IGF2BP2 TUBG2
Leg fat-free mass (left)	2.53	6	4	8.9	0.72	1.1e-01	FNDC4 NAPEPLD RBL2 RBM6 RP11-69E11.4 TUBG2
Leg predicted mass (left)	2.52	6	4	8.9	0.72	1.1e-01	FNDC4 NAPEPLD RBL2 RBM6 RP11-69E11.4 TUBG2
Systolic Blood Pressure	2.50	9	4	8.9	0.72	3.0e-02	CAMK1D FNDC4 JAZF1 KCNJ11 PMS2P5 TCF7L2 TCTA ZBTB46 ZNF517
Body fat percentage	2.48	7	4	8.9	0.14	7.6e-01	CLEC18A PMS2P5 RBM6 TCF7L2 TCTA TUBG2 ZCCHC24
Fluid intelligence score	2.45	4	1	2.2	-0.67	3.3e-01	KCNJ11 RBL2 RBM6 TCTA
Leg fat-free mass (right)	2.43	5	4	8.9	0.67	2.1e-01	FNDC4 RBL2 RBM6 RP11-69E11.4 TUBG2
Leg predicted mass (right)	2.42	5	4	8.9	0.67	2.1e-01	FNDC4 RBL2 RBM6 RP11-69E11.4 TUBG2
Trunk fat mass	2.41	7	4	8.9	0.37	4.2e-01	CLEC18A PMS2P5 RBM6 RP11-69E11.4 TCF7L2 TCTA TUBG2
Hip circumference	2.38	8	4	8.9	0.13	7.7e-01	CLEC18A FNDC4 NAPEPLD PMS2P5 RBL2 RBM6 RP11-69E11.4 TCF7L2
Lung FEV1/FVC ratio	2.37	5	5	11.1	-0.84	7.5e-02	AC010883.5 CAMK1D IGF2BP2 LOC100133893 RP11-69E11.4
Blood White Count	2.32	7	3	6.7	-0.06	9.0e-01	CLEC18A FNDC4 PVRL2 RBM6 RP11-69E11.4 TUBG2 ZBTB46
Comparative height size at age 10	2.32	6	5	11.1	-0.01	9.8e-01	AC010883.5 FNDC4 JAZF1 KCNJ11 RBL2 UBE2E2
Heel bone mineral density (BMD) T-score, automated (left)	2.26	3	2	4.4	0.00	1.0e+00	AC010883.5 RBM6 TCTA
Illnesses of mother	2.25	2	0	0.0	0.00	1.0e+00	IGF2BP2 TCTA
Height	2.20	9	7	15.6	0.21	5.9e-01	AC010883.5 AP3S2 CLEC18A FNDC4 JAZF1 KCNJ11 RBL2 SSR1 UBE2E2
Age at first live birth	2.20	2	1	2.2	0.00	1.0e+00	RBM6 TCTA
Lung FVC	2.19	9	3	6.7	-0.82	6.4e-03	CAMK1D CHMP4B CLEC18A FNDC4 IGF2BP2 JAZF1 SSR1 ZBTB46 ZCCHC24
Intelligence (Savage-Jansen 2018)	2.17	2	2	4.4	0.00	1.0e+00	RBL2 RBM6
Qualifications: A levels/AS levels or equivalent	2.16	2	1	2.2	0.00	1.0e+00	RBM6 TCTA
Standing height	2.15	6	6	13.3	0.40	4.4e-01	CLEC18A FNDC4 JAZF1 KCNJ11 RBL2 SSR1
Verbal and Numeric Reasoning (VNR)	2.14	3	2	4.4	0.00	1.0e+00	RBL2 RBM6 TCTA
Birth weight of first child	2.13	2	0	0.0	0.00	1.0e+00	RBL2 SSR1
Hayfever, allergic rhinitis or eczema	2.12	5	1	2.2	-0.52	3.7e-01	AC010883.5 FNDC4 JAZF1 TUBG2 UBE2D3
Forced expiratory volume in 1-second (FEV1)	2.12	5	2	4.4	-0.94	2.0e-02	CAMK1D CLEC18A IGF2BP2 SMYD2 ZCCHC24
Forced expiratory volume in 1-second (FEV1), Best measure	2.12	4	2	4.4	-0.92	7.6e-02	CAMK1D CLEC18A IGF2BP2 ZCCHC24
HDL Cholesterol	2.11	2	1	2.2	0.00	1.0e+00	RBM6 RP11-69E11.4
Heel T-Score	2.09	9	6	13.3	0.58	1.0e-01	AC010883.5 IGF2BP2 PMS2P5 RBM6 RP11-69E11.4 SMYD2 SSR1 TCTA TUBG2
Trunk fat percentage	2.08	6	3	6.7	0.93	6.9e-03	CLEC18A PMS2P5 RBM6 TCTA TUBG2 ZCCHC24
Asthma (self-reported)	2.07	5	0	0.0	0.26	6.7e-01	EIF2S2P3 JAZF1 PVRL2 RBM6 TUBG2
Heel bone mineral density (BMD) T-score, automated (right)	2.06	2	2	4.4	0.00	1.0e+00	RBM6 TCTA
Mouth/teeth dental problems: Dentures	2.05	2	0	0.0	0.00	1.0e+00	PMS2P5 RBM6
Asthma	2.05	5	0	0.0	0.28	6.5e-01	EIF2S2P3 JAZF1 PVRL2 RBM6 TUBG2
Allergy or Eczema	2.00	5	1	2.2	-0.49	4.0e-01	AC010883.5 FNDC4 JAZF1 TUBG2 UBE2D3
Respiratory disease	2.00	4	0	0.0	0.39	6.1e-01	EIF2S2P3 JAZF1 PVRL2 RBM6
Tanning	2.00	4	4	8.9	0.86	1.4e-01	CHMP4B FNDC4 JAZF1 NOTCH2
Systolic blood pressure, automated reading	1.99	5	2	4.4	1.00	4.2e-04	CAMK1D KCNJ11 PMS2P5 TCTA ZBTB46
Qualifications: NVQ or HND or HNC or equivalent	1.97	1	0	0.0	0.00	1.0e+00	RBM6
Allergy	1.94	4	0	0.0	-0.37	6.3e-01	AC010883.5 JAZF1 TUBG2 UBE2D3
Age when periods started (menarche)	1.92	2	2	4.4	0.00	1.0e+00	CLEC18A PMS2P5
Peak expiratory flow (PEF)	1.91	4	2	4.4	-0.98	1.8e-02	AC010883.5 CAMK1D CLEC18A IGF2BP2
Qualifications: College or University degree	1.89	2	1	2.2	0.00	1.0e+00	RBL2 RBM6
High blood pressure (siblings)	1.86	1	0	0.0	0.00	1.0e+00	FNDC4
Medication for pain relief, constipation, heartburn	1.86	1	0	0.0	0.00	1.0e+00	UBE2D3
Angina	1.84	1	0	0.0	0.00	1.0e+00	ZBTB46
Ulcerative Colitis (UC)	1.82	1	0	0.0	0.00	1.0e+00	AC010883.5
Relative age of first facial hair	1.82	3	1	2.2	0.00	1.0e+00	FNDC4 LOC100133893 PMS2P5
Angina (self-reported)	1.82	1	0	0.0	0.00	1.0e+00	ZBTB46
Illnesses of father: Heart disease	1.82	1	0	0.0	0.00	1.0e+00	ZCCHC24
Forced expiratory volume in 1-second (FEV1), predicted	1.82	2	1	2.2	0.00	1.0e+00	JAZF1 KCNJ11
Knee pain experienced in last month	1.79	2	0	0.0	0.00	1.0e+00	RBM6 ZCCHC24
Maternal smoking around birth	1.78	1	0	0.0	0.00	1.0e+00	CLEC18A
Sitting height	1.77	9	5	11.1	0.13	7.4e-01	CLEC18A FNDC4 JAZF1 RBL2 RP11-69E11.4 SSR1 UBE2E2 UBE3C ZCCHC24
Diastolic blood pressure, automated reading	1.77	3	2	4.4	0.00	1.0e+00	PMS2P5 RBM6 TCTA
Heart attack	1.76	1	0	0.0	0.00	1.0e+00	AC010883.5
Medication: Bendroflumethiazide	1.76	1	0	0.0	0.00	1.0e+00	ZNF517
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.73	3	1	2.2	0.00	1.0e+00	CAMK1D IGF2BP2 JAZF1
Forced vital capacity (FVC)	1.72	5	1	2.2	-0.64	2.5e-01	CAMK1D CLEC18A SMYD2 SSR1 ZCCHC24
Forced vital capacity (FVC), Best measure	1.72	5	2	4.4	-0.18	7.8e-01	CAMK1D CLEC18A JAZF1 SSR1 ZCCHC24
Medication: Ventolin 100micrograms inhaler	1.71	1	0	0.0	0.00	1.0e+00	RBM6
Pack years adult smoking proportion	1.70	2	0	0.0	0.00	1.0e+00	CLEC18A PMS2P5
Fed-up feelings	1.70	2	0	0.0	0.00	1.0e+00	AC010883.5 RBM6
Pack years of smoking	1.70	2	0	0.0	0.00	1.0e+00	CLEC18A PMS2P5
Schizophrenia vs Biploar Disorder	1.66	2	0	0.0	0.00	1.0e+00	FNDC4 RBM6
Prospective memory result	1.62	1	0	0.0	0.00	1.0e+00	RBM6
Ever highly irritable/argumentative for 2 days	1.58	1	0	0.0	0.00	1.0e+00	RBM6
Heart attack/myocardial infarction (self-reported)	1.58	1	0	0.0	0.00	1.0e+00	AC010883.5
Mouth/teeth dental problems	1.57	1	0	0.0	0.00	1.0e+00	PMS2P5
Reaction Time	1.56	1	0	0.0	0.00	1.0e+00	TCTA
Health satisfaction	1.56	1	0	0.0	0.00	1.0e+00	RBM6
Mood swings	1.56	1	0	0.0	0.00	1.0e+00	RBM6
Bipolar Disorder (2018)	1.55	1	0	0.0	0.00	1.0e+00	FNDC4
Hand grip strength (right)	1.53	2	1	2.2	0.00	1.0e+00	CLEC18A FNDC4
Medication: Seretide 50 evohaler	1.53	1	0	0.0	0.00	1.0e+00	RBM6
Qualifications: nursing, teaching	1.52	2	0	0.0	0.00	1.0e+00	RBM6 TCF7L2
Mouth/teeth dental problems: Bleeding gums	1.51	1	0	0.0	0.00	1.0e+00	WFS1
Relative age voice broke	1.50	2	0	0.0	0.00	1.0e+00	PMS2P5 TCTA
Chronotype (morning person)	1.49	1	1	2.2	0.00	1.0e+00	NAPEPLD
Qualifications: None of the above	1.49	2	1	2.2	0.00	1.0e+00	RBL2 RBM6
Falls in the last year	1.49	1	0	0.0	0.00	1.0e+00	CLEC18A
Financial situation satisfaction	1.49	1	0	0.0	0.00	1.0e+00	RBM6
Number of live births	1.48	1	0	0.0	0.00	1.0e+00	RBM6
Mean time to correctly identify matches	1.48	2	0	0.0	0.00	1.0e+00	RBM6 TCTA
Hair/balding pattern: Pattern 4	1.47	2	0	0.0	0.00	1.0e+00	AC010883.5 NOTCH2
Hayfever/allergic rhinitis (self-reported)	1.44	2	0	0.0	0.00	1.0e+00	NAPEPLD TUBG2
Breastfed as a baby	1.44	1	0	0.0	0.00	1.0e+00	TCTA
Hearing difficulty/problems with background noise	1.42	1	0	0.0	0.00	1.0e+00	TUBG2
Age started oral contraceptive pill	1.42	1	0	0.0	0.00	1.0e+00	RBM6
Osteoporosis (self-reported)	1.40	1	0	0.0	0.00	1.0e+00	TCTA
Alzheimer’s Disease (in mother)	1.38	1	0	0.0	0.00	1.0e+00	PVRL2
Chronic bronchitis/emphysema (mother)	1.38	1	0	0.0	0.00	1.0e+00	RBM6
Depressed Affect (Nagel 2018)	1.34	2	0	0.0	0.00	1.0e+00	AC010883.5 RBM6
Leg pain on walking	1.33	1	0	0.0	0.00	1.0e+00	RBM6
Miserableness	1.32	1	1	2.2	0.00	1.0e+00	RBM6
Mouth/teeth dental problems: Mouth ulcers	1.30	1	0	0.0	0.00	1.0e+00	TUBG2
Pain experienced in last month	1.30	1	0	0.0	0.00	1.0e+00	RBM6
Hypothyroidism (self reported)	1.28	2	0	0.0	0.00	1.0e+00	AC010883.5 IGF2BP2
Hand grip strength (left)	1.28	1	0	0.0	0.00	1.0e+00	CLEC18A
Other serious medical condition/disability diagnosed by doctor	1.27	1	0	0.0	0.00	1.0e+00	PMS2P5
Blood Eosinophil Count	1.26	6	4	8.9	0.28	5.9e-01	AC010883.5 CLEC18A EIF2S2P3 JAZF1 PVRL2 RBM6
Neck or shoulder pain in last month	1.24	1	0	0.0	0.00	1.0e+00	RP11-69E11.4
Eye problems/disorders: Cataract	1.24	1	0	0.0	0.00	1.0e+00	CHMP4B
Neuroticism score	1.22	2	0	0.0	0.00	1.0e+00	AC010883.5 RBM6
Hair Pigment	1.21	8	3	6.7	-0.38	3.6e-01	AC010883.5 CHMP4B FNDC4 JAZF1 NAPEPLD RP11-69E11.4 SSR1 ZCCHC24
Alzheimer’s Disease (in father)	1.18	1	0	0.0	0.00	1.0e+00	PVRL2
Medication: Co-codamol	1.17	1	0	0.0	0.00	1.0e+00	RBM6
Schizophrenia (2014)	1.15	1	0	0.0	0.00	1.0e+00	KCNJ11
Blood Red Count	1.15	6	2	4.4	0.95	3.8e-03	FNDC4 IGF2BP2 RBM6 TCTA UBE2D3 ZBTB46
Irritability	1.14	1	0	0.0	0.00	1.0e+00	AC010883.5
Frequency of tenseness / restlessness in last 2 weeks	1.13	1	0	0.0	0.00	1.0e+00	RBM6
Average weekly beer plus cider intake	1.13	1	0	0.0	0.00	1.0e+00	RBM6
Neuroticism (Nagel 2018)	1.12	1	0	0.0	0.00	1.0e+00	AC010883.5
Father's age at death	1.11	1	0	0.0	0.00	1.0e+00	TUBG2
Comparative body size at age 10	1.10	1	0	0.0	0.00	1.0e+00	FNDC4
Hypothyroidism/myxoedema (self-reported)	1.08	1	0	0.0	0.00	1.0e+00	IGF2BP2
Neuroticism	1.03	1	0	0.0	0.00	1.0e+00	RBM6
LDL Cholesterol	1.01	1	0	0.0	0.00	1.0e+00	FNDC4
Smoking Status	0.99	2	0	0.0	0.00	1.0e+00	CLEC18A KCNJ11

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Artery Aorta	3	0.101	1.8
GTEx	Brain Cerebellum	1	0.050	1.8
GTEx	Brain Cortex	1	0.097	1.8
GTEx	Esophagus Muscularis	3	0.093	1.8
GTEx	Ovary	1	0.110	1.8
GTEx	Skin Not Sun Exposed Suprapubic	3	0.122	1.8
GTEx	Thyroid	5	0.125	1.8
GTEx	Adipose Subcutaneous	2	0.057	1.7
GTEx	Adipose Visceral Omentum	0	0.000	1.7
GTEx	Artery Tibial	1	0.027	1.7
GTEx	Brain Cerebellar Hemisphere	1	0.067	1.7
GTEx	Breast Mammary Tissue	2	0.101	1.7
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.7
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.7
GTEx	Cells EBV-transformed lymphocytes	0	0.000	1.7
GTEx	Cells Transformed fibroblasts	4	0.095	1.7
GTEx	Colon Sigmoid	0	0.000	1.7
GTEx	Colon Transverse	1	0.048	1.7
GTEx	Esophagus Gastroesophageal Junction	2	0.138	1.7
GTEx	Esophagus Mucosa	4	0.120	1.7
GTEx	Heart Atrial Appendage	2	0.127	1.7
GTEx	Lung	2	0.070	1.7
GTEx	Muscle Skeletal	2	0.069	1.7
GTEx	Nerve Tibial	2	0.046	1.7
GTEx	Pancreas	1	0.061	1.7
GTEx	Pituitary	1	0.090	1.7
GTEx	Prostate	1	0.120	1.7
GTEx	Skin Sun Exposed Lower leg	3	0.082	1.7
GTEx	Vagina	0	0.000	1.7
GTEx	Whole Blood	2	0.100	1.7
CommonMind	Brain Pre-frontal Cortex	6	0.112	1.7
The Cancer Genome Atlas	Colon Adenocarcinoma	3	0.145	1.7
The Cancer Genome Atlas	Soft Tissue Sarcoma	2	0.187	1.7
GTEx	Adrenal Gland	2	0.137	1.6
GTEx	Artery Coronary	1	0.085	1.6
GTEx	Brain Frontal Cortex BA9	0	0.000	1.6
GTEx	Brain Hippocampus	0	0.000	1.6
GTEx	Brain Nucleus accumbens basal ganglia	1	0.116	1.6
GTEx	Brain Putamen basal ganglia	0	0.000	1.6
GTEx	Heart Left Ventricle	0	0.000	1.6
GTEx	Small Intestine Terminal Ileum	0	0.000	1.6
GTEx	Spleen	1	0.071	1.6
GTEx	Stomach	0	0.000	1.6
GTEx	Testis	5	0.158	1.6
METSIM	Adipose	5	0.108	1.6
NTR	Blood	5	0.208	1.6
ROSMAP	Brain Pre-frontal Cortex	3	0.068	1.6
YFS	Blood	2	0.043	1.6
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	3	0.181	1.6
The Cancer Genome Atlas	Breast Invasive Carcinoma	2	0.045	1.6
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	1	0.091	1.6
The Cancer Genome Atlas	Esophageal Carcinoma	1	0.146	1.6
The Cancer Genome Atlas	Glioblastoma Multiforme	1	0.098	1.6
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	4	0.147	1.6
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	4	0.098	1.6
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	3	0.146	1.6
The Cancer Genome Atlas	Brain Lower Grade Glioma	4	0.093	1.6
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	1	0.090	1.6
The Cancer Genome Atlas	Lung Adenocarcinoma	4	0.136	1.6
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	1	0.060	1.6
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	1	0.075	1.6
The Cancer Genome Atlas	Prostate Adenocarcinoma	1	0.022	1.6
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.187	1.6
The Cancer Genome Atlas	Thyroid Carcinoma	4	0.078	1.6
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	1	0.197	1.6
GTEx	Brain Caudate basal ganglia	0	0.000	1.5
GTEx	Brain Hypothalamus	0	0.000	1.5
GTEx	Liver	1	0.139	1.5
GTEx	Uterus	0	0.000	1.5
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	2	0.080	1.5
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	2	0.126	1.5
The Cancer Genome Atlas	Rectum Adenocarcinoma	1	0.145	1.5
The Cancer Genome Atlas	Stomach Adenocarcinoma	1	0.059	1.5
The Cancer Genome Atlas	Testicular Germ Cell Tumors	2	0.156	1.5